Scarica l'app Stockscreener
6.11
0.65%
-0.04
Precedente Chiudi:
$6.15
Aprire:
$6.13
Volume 24 ore:
87,818
Relative Volume:
0.54
Capitalizzazione di mercato:
$97.70M
Reddito:
$5.12M
Utile/perdita netta:
$-67.00M
Rapporto P/E:
-4.1565
EPS:
-1.47
Flusso di cassa netto:
$-38.94M
1 W Prestazione:
+15.07%
1M Prestazione:
+7.38%
6M Prestazione:
+28.63%
1 anno Prestazione:
+3.37%
Intervallo 1D:
$5.96
$6.34
Intervallo di 1 settimana:
$5.05
$6.56
Portata 52W:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Nome
Verrica Pharmaceuticals Inc
Settore
Industria
Telefono
484-453-3300
Indirizzo
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
6.11 | 97.70M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2023-03-22 | Iniziato | Jefferies | Buy |
| 2023-02-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-06-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-24 | Iniziato | Northland Capital | Outperform |
| 2020-03-24 | Iniziato | Needham | Buy |
| 2019-02-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability - simplywall.st
Verrica Pharmaceuticals Gains CHMP Support for YCANTH® Marketing Application in Europe - MSN
Verrica Pharmaceuticals Achieves 130% YCANTH Revenue Growth in 2025, Expands Global Pipeline, and Extends Cash Runway into 2027 - Minichart
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Verrica Pharmaceuticals Q4 2025 sees revenue surge By Investing.com - Investing.com South Africa
Earnings call transcript: Verrica Pharmaceuticals Q4 2025 sees revenue surge - Investing.com Canada
YCANTH (VP-102): FDA-Approved Treatment for Molluscum Contagiosum and Dermatology Pipeline Overview | 2025 10-K Highlights - Minichart
VRCA: Revenue surged 368% in 2025, with strong YCANTH growth, cost cuts, and pipeline advances - TradingView
Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results - MarketBeat
Verrica (VRCA) Achieves Strong Financial Milestones in 2025 - GuruFocus
Verrica Pharmaceuticals 2025 10-K: $35.6M Revenue, $(1.68) EPS - TradingView
[10-K] Verrica Pharmaceuticals Inc. Files Annual Report | VRCA SEC FilingForm 10-K - Stock Titan
Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand - TradingView
VRCA: Revenue up 370% in 2025, net loss narrowed, debt repaid, and YCANTH sales nearly doubled - TradingView
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Zacks Research to Hold - MarketBeat
Earnings Outlook For Verrica Pharmaceuticals - Benzinga
FRAUD AND MANIPULATION—E.D. Pa.: Class certified in action against pharma company for allegedly misleading investors - VitalLaw.com
Verrica Pharmaceuticals Schedules Conference Call to Discuss 2025 Results - MyChesCo
Verrica Secures $10 Million Milestone as YCANTH Wins Approval in Japan - MSN
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISI - GuruFocus
West Chester-based Verrica partner launches YCANTH in Japan - MSN
Is Verrica Pharmaceuticals Inc stock good for income investorsPortfolio Gains Summary & Safe Capital Growth Tips - baoquankhu1.vn
Aug Highlights: Can Verrica Pharmaceuticals Inc continue delivering strong returnsJuly 2025 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Verrica Pharmaceuticals Inc expected to post a loss of 79 cents a shareEarnings Preview - TradingView
Verrica Investors Gain Class Status Over Delayed FDA Approval - Bloomberg Law News
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Sahm
Pharma Co. Investors Secure Class Cert. Over FDA Obstacles - Law360
Verrica Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Verrica schedules March 11 call on 2025 results and skin drug business - Stock Titan
Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Verrica Pharmaceuticals at TD Cowen Conference: Strategic Insights By Investing.com - Investing.com Canada
VRCA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VRCA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Common Warts Market: Expanding Revenue Landscape To 2034 Delveinsight Nielsen Biosciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Mena FN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Fed Impact: How does Verrica Pharmaceuticals Inc score in quality rankingsEarnings Overview Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - Yahoo Finance
How does Verrica Pharmaceuticals Inc. perform in inflationary periodsExit Point & Smart Allocation Stock Tips - mfd.ru
Verrica Pharmaceuticals: Strategic Execution Takes Center Stage - AD HOC NEWS
West Chester-Based Verrica Partner Launches YCANTH in Japan - MyChesCo
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer - MyChesCo
Verrica Pharmaceuticals Launches YCANTH in Japan with Torii Pharmaceutical - Intellectia AI
Verrica Pharma appoints Chris Chapman as CCO - The Pharma Letter
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - marketscreener.com
What’s the outlook for Verrica Pharmaceuticals Inc.’s sector2025 Year in Review & Real-Time Buy Signal Notifications - mfd.ru
Verrica Pharmaceuticals Inc. Appoints Chris Chapman as Chief Commercial Officer - marketscreener.com
Verrica Pharmaceuticals (VRCA) Appoints New Chief Commercial Off - GuruFocus
Verrica Pharmaceuticals Appoints Chris Chapman As Chief Commercial Officer - TradingView
Verrica Pharmaceuticals Inc Azioni (VRCA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):